Pulmonary Hypertension Clinical Trial
Official title:
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Verified date | February 2024 |
Source | Biogen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.
Status | Completed |
Enrollment | 166 |
Est. completion date | May 16, 2018 |
Est. primary completion date | January 19, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Adult male and female patients = 18 to = 75 years of age upon study consent; 2. BMI > 18.5 kg/m² 3. Symptomatic pulmonary hypertension WHO class II and III; 4. WHO Group I, III, or V PH according to the following criteria: 1. If diagnosed with WHO Group I PAH, then on of the following subtypes: - Idiopathic or heritable PAH; - PAH associated with connective tissue disease; - PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following shunt repair; - PAH associated with anorexigen or drug-induced toxicity; - PAH associated with human immunodeficiency virus (HIV); or 2. If WHO Group III PH then primary diagnosis must be one of the following subtypes: - Connective tissue disease associated ILD (CTD-ILD); - Idiopathic pulmonary fibrosis (IPF); - Nonspecific interstitial pneumonia (NSIP); or 3. If WHO Group V PH then patient must be diagnosed with sarcoidosis; 5. Had a diagnostic right heart catheterization performed and documented within 36 months prior to Day 1 that confirmed a diagnosis of PH 6. If WHO Group I, has been receiving no more than three (3) FDA-approved disease-specific PAH therapies except for intravenous (iv) prostacyclin/prostacyclin analogues. PAH therapy must be at a stable dose for at least 90 days prior to Day 1; 7. Has adequate kidney function defined as an estimated glomerular filtration rate (eGFR) = 45 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) 4-variable formula; Exclusion Criteria: 1. Participation in other interventional clinical studies involving pharmaceutical products being tested or used in a way different from the approved form or when used for an unapproved indication within 30 days prior to Day 1; 2. Initiation of an exercise program for cardio-pulmonary rehabilitation within 3 months (90 days) prior to Day 1 or planned initiation during Part 1 of the study; 3. Stopped receiving any PH chronic therapy within 60 days prior to Day 1; 4. Requirement for receipt of intravenous inotropes within 30 days prior to Day 1; 5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg during Screening after a period of rest; 6. Has systolic BP < 90 mm Hg during Screening after a period of rest; 7. WHO Group III or V patients who at rest require supplemental oxygen at a rate of >4 L/min and have peripheral capillary oxygen saturation levels <92%; 8. Has a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease,including but not limited to any of the following: 1. Congenital or acquired valvular disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension; 2. Pericardial constriction; 3. Restrictive or congestive cardiomyopathy; 4. Left ventricular ejection fraction < 40% per echocardiogram (ECHO) within 60 days of Day 1; 5. Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or anginal chest pain); 9. Acutely decompensated heart failure within 30 days prior to Day 1, as per Investigator assessment; 10. History of atrial septostomy within 180 days prior to Day 1; 11. History of obstructive sleep apnea that is untreated; 12. Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C); 13. Serum aminotransferase (ALT or AST) levels > the upper limit of normal (ULN) at Screening; 14. For patients with HIV-associated PAH, any of the following: 1. Concomitant active opportunistic infections within 180 days prior to Screening; 2. Detectable viral load within 90 days prior to Screening; 3. Cluster designation (CD+) T-cell count < 200 mm3 within 90 days prior to Screening; 4. Changes in antiretroviral regimen within 90 days prior to Screening; 5. Using inhaled pentamidine |
Country | Name | City | State |
---|---|---|---|
Germany | University Clinic Carl Gustav Carus | Dresden | |
Germany | Universitaetsklinikum Hamburg-Eppendorf | Hamburg | |
United States | University of Colorado Denver - Division of Pulmonary Sciences | Aurora | Colorado |
United States | Cedars Sinai Medical Center | Beverly Hills | California |
United States | Boston University School of Medicine | Boston | Massachusetts |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Tufts Medical Center | Boston | Massachusetts |
United States | University of Chicago | Chicago | Illinois |
United States | The Lindner Clinical Trial Center | Cincinnati | Ohio |
United States | University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine | Cincinnati | Ohio |
United States | The Ohio State University Wexner Medical Center | Columbus | Ohio |
United States | University of Texas Southwestern Medical Center | Dallas | Texas |
United States | BreatheAmerica El Paso, Inc. | El Paso | Texas |
United States | Houston Methodist Research Institute | Houston | Texas |
United States | The University of Texas - Health Science Center & Medical School at Houston | Houston | Texas |
United States | University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics | Houston | Texas |
United States | South Denver Cardiology Associates, P.C | Littleton | Colorado |
United States | VA Healthcare System of Greater Los Angeles | Los Angeles | California |
United States | Winthrop University Hospital | Mineola | New York |
United States | Mount Sinai, Beth Israel Medical Center | New York | New York |
United States | Weill Cornell Medical Center | New York | New York |
United States | Oklahoma Heart Hospital | Oklahoma City | Oklahoma |
United States | Arizona Pulmonary Specialists | Phoenix | Arizona |
United States | Banner University Medical Center, Phoenix Advanced Lung Disease Institute | Phoenix | Arizona |
United States | University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania |
United States | Maine Medical Center - Division of Pulmonary and Critical Care Medicine | Portland | Maine |
United States | University of Rochester - University of Rochester Medical Center | Rochester | New York |
United States | University of California Davis Medical Center - Division of Pulmonary and Critical Care | Sacramento | California |
United States | University of Utah | Salt Lake City | Utah |
United States | Harbor - UCLA Medical Center | Torrance | California |
United States | Georgetown University Medical Center - Department of Rheumatology | Washington | District of Columbia |
United States | Cleveland Clinic of Florida | Weston | Florida |
Lead Sponsor | Collaborator |
---|---|
Reata, a wholly owned subsidiary of Biogen |
United States, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline Though Week 16 in 6-Minute Walk Distance (6MWD) for Bardoxolone Methyl Compared to Placebo | Overall treatment effect in exercise capacity, as measured by the total distance walked in 6 minutes (6MWD) mean change from baseline though Week 16. A lower 6MWD reflects greater severity thus, a positive change from baseline suggests an improvement. | Baseline through Week 16 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A | |
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 |